Australia is experience innovative treatment for obesity: Retatrutide. The dual agonist – acting on both GLP-1 and GIP receptors – demonstrates significant outcomes in international studies, suggesting considerable drops in weight. While availability hasn't occurred with the Therapeutic Goods Adm